Improving Outcomes in Advanced Lung Cancer : Maintenance therapy in non-small-cell lung carcinoma by Furrukh, Muhammad et al.
Sultan Qaboos University Med J, February 2013, Vol. 13, Iss. 1, pp. 3-18, Epub. 27th Feb 13
Submitted 4TH Jun 12
Revision Req. 8TH Aug 12, Revision Recd. 30TH Aug 12
Accepted 14TH Oct 12
Lung cancer is the most common cancer worldwide and a leading cause of cancer-related deaths (19.4%). The Global 
Cancer Incidence Project (GLOBOCAN) estimated 
12.7 million new cancers and 7.6 million cancer 
deaths worldwide in 2008. Lung cancer accounts 
for 1.6 million new registered cases and 1.37 million 
deaths around the globe in the same year.1 The 
American Cancer Society (ACS) estimated that 
there were 226,160 lung cancer cases and 160,340 
lung cancer-related deaths in 2010 in the United 
States alone. The incidence of lung cancer is higher 
among men when compared to women, accounting 
for 34% and 13.5% of all cancers, respectively. The 
age-standardised ratio for its incidence is 33.81%, 
and has a 29.2% rate in men.2 The ACS numbers 
currently place the adenocarcinoma subtype at 40% 
of all the reported cases.3 In 2000–2003, the US 
Surveillance Epidemiology and End Results (SEER) 
database also described it as the most prevalent 
(47%) lung cancer subtype regardless of race, age, or 
gender, and the shift in histology was attributed to 
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حتسني النتائج يف سرطان الرئة املتقدم
العالج املستدام يف سرطان الرئة ذي اخللية غري الصغرية
حممد فروخ، اإكرام برين، �صيام كومار، فرحان خوجه، من�صور املنذري
 )NSCLC(امللخ�ص: ظل العالج الكيميائي هو العالج التقليدي لعالج �رسطان الرئة ذي اخللية، معززا معدل البقاء على قيد احلياة يف
2008م. و يف  اأوائل عام  اأ�صهر حتى  الع�رسة  البقاء يف حدود  ا�صتقر متو�صط  %29. وقد  اإىل  الأوىل  ال�صنة  ال�صغرية املنت�رسة يف  غري 
حماولة  لتعزيز فر�ض احلياة يف املراحل املتقدمة من املر�ض، بداأت درا�صات العالج امل�صتدام الكيميائي والتي اأثبتت موؤخراً اإطالة اأمد 
البقاء �صهرين اأو ثالثة اأ�صهر اإ�صافية يف حالة املر�صى الذين كان اإجنازهم الأدائي )1-0 ( مع احتفاظهم باأداء اع�صاء ج�صمهم ب�صكل 
اأف�صل  جيد. يتم عالج املر�صى املرجو من ا�صتفادتهم الإكلينيكية باأربعة اإىل �صتة دورات من العالج الكيميائي ثم ي�صتخدم واحد من 
تلك العنا�رس املكونة للعالج الكيميائي حتى الو�صول لأف�صل ا�صتجابة اأو حدوث م�صاعفات جانبية )املداومة امل�صتكملة( اأو تغريها اإىل 
عن�رس اآخر )املداومة املبدلة(. املقالة ت�صتعر�ض باإيجاز تطور العالج الكيميائي التقليدي وت�صف التجارب الرئي�صية من العالج امل�صتدام 
املتكون من العالج الكيميائي والأدوية امل�صتهدفة يف حماولة لتح�صني النتائج يف �رسطان الرئة ذي اخللية غري ال�صغرية.
مفتاح الكلمات: �رسطان الرئة ذي اخللية غري ال�صغرية؛ اأورام الرئة؛ العالج امل�صتدام الكيميائي؛ العالج اجلزيئي امل�صتهدف؛ م�صتقبالت؛عامل 
.A منو الب�رسة؛ عامل منو بطانة الأوعية
abstract: Systemic chemotherapy has remained the traditional treatment for metastatic non-small-cell lung 
carcinoma (NSCLC), enhancing survival rate at 1 year to 29%. The median survival had plateaued at around 10 
months until early 2008, and in an attempt to enhance survival in advanced disease, maintenance chemotherapy 
trials were initiated which had recently demonstrated prolongation of survival by an additional 2–3 months 
in patients who had performance status (PS) 0–1 and well-preserved organ functions. Suitable patients with 
any degree of clinical benefit are treated with 4–6 cycles, and then one of the active agents is continued until 
best response, or toxicity (continued maintenance), or changed to a cross non-resistant single agent (switch 
maintenance). The article briefly reviews the evolution of systemic therapy and describes key randomised trials 
of maintenance therapy instituting chemotherapy and targeted agents in an attempt to improve outcomes in 
advanced metastatic NSCLC, based on certain clinical features, histology, and genetics. 
Keywords: Carcinoma; Non-small-cell lung; Lung neoplasm; Maintenance chemotherapy; Molecular targeted 
therapy; Receptor; Epidermal growth factor; Vascular endothelial growth factor A.
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changes in the manufacturing of cigarettes, creating 
filters that allow deeper inhalation, thus channelling 
smoke towards the distal bronchioles.4 
Based on a 2010 report on cancer incidence 
in Oman, published by the Ministry of Health, 
between 1998 and 2007 lung cancer was the fifth 
most common  cancer in Oman compared to other 
Gulf Cooperation Council (GCC) countries. In 
2010, it was the eighth commonest cause of  cancer 
deaths among men (4.5%).5 It was also reported 
to be the most common cause of cancer-related, 
hospital-based deaths in 2008 and the second 
most common cause in 2010, representing 8.78% 
of all cancer deaths, following stomach cancer.5,6 
The age-standardised incidence rate was 4.2 and 
0.7 per 100,000 per year, and the crude incidence 
was 1.9 and 0.3 in men and women, respectively. 
The disease ranks first as a cause of cancer-related 
deaths in Qatar, the United Arab Emirates (UAE), 
and Bahrain. In Oman, small cell lung cancer 
(SCLC) accounted for 12% and non-small-cell 
lung cancer (NSCLC) for 88% of all the cancers 
reported in those countries. Among NSCLCs, 
the adenocarcinoma subtype accounted for 34%, 
squamous cell carcinoma around 22%, and other 
specified carcinomas and not otherwise specified 
subtypes accounted for 16% of cases.5
Traditionally, advanced metastatic NSCLC was 
treated with palliative systemic chemotherapy, 
but the majority of those patients experienced 
disease progression shortly after the cessation 
of chemotherapy, including those who initially 
responded to such an intervention. Recently, 
maintenance therapy has emerged as a new hope 
for these patients with improved outcomes and 
is associated with prolongation of survival by 
a median of two to three months. This article 
describes the consistent gains in survival over the 
past few decades and current evidence related to 
maintenance therapy, and also tries to identify 
patient subsets which are most likely to benefit 
from maintenance therapy.
Methods
Data was identified from searches in Medscape, 
PubMed, Google, and key cancer groups such as the 
American Society of Clinical Oncology (ASCO), 
National Comprehensive Cancer Network (NCCN), 
and the European Society for Medical Oncology 
(ESMO) by using terms such as ‘chemotherapy 
in metastatic or advanced non-small-cell lung 
cancer’, ‘maintenance chemotherapy’, ‘consolidation 
therapy’, and ‘molecular targeted therapy’. Reference 
was also made to key phase II and III trials and 
meta-analyses published in reputable oncology 
journals (e.g. Journal of Clinical Oncology, the New 
England Journal of Medicine, Oncologist, Lancet 




Patients with untreated advanced or metastatic 
disease have a median survival period of 
~4 months, and can expect a one-year survival 
period in 10% of cases when managed with best 
supportive care (BSC).7 Systemic chemotherapy 
remains the standard treatment for advanced or 
metastatic NSCLC, especially for patients who do 
not harbour somatic mutations of the epidermal 
growth factor receptor (EGFR) gene. A meta-analysis 
in 1995 showed that the use of cisplatin-containing 
chemotherapy was found to be associated with a 
27% reduction in the risk of death, and improvement 
of 10% in survival, to attain a cumulative survival 
of 20% at one-year when compared to BSC alone 
(P <0.0001).8 
Poly-chemotherapy with a cisplatin backbone 
remained the gold standard based on two meta- 
analyses in advanced NSCLC. In studies of cisplatin 
versus carboplatin by Hotta et al., patients with 
metastatic lung cancer were evaluated during 
treatment, revealing that cisplatin was marginally 
superior to carboplatin. The studies also found 
that the addition of a third generation agent to 
cisplatin was associated with an 11% longer survival 
compared to cisplatin being used alone.9,10 Large 
randomised phase III trials also have shown that 
platinum-doublets, (with gemcitabin, docetaxel, 
or vinorelbine) yielded a median overall survival 
(OS) of 8–10 months. A meta-analysis of 65 trials, 
including 13,601 patients, confirmed that the use of 
doublet chemotherapy increased the response rates 
(RR) and the median survival rates at one year by 
20% when compared to single agent therapy. Adding 
a third agent to platinum doublets enhanced the 
response rates but not the survival and were more 
toxic.11
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with marginal renal functions and is associated with 
higher rates of thrombocytopenia, especially when 
used in combination with gemcitabine, but needs 
less hydration. 
Two separate meta-analyses of over 12,000 
patients combined compared responses, survival, 
toxicity, and cost of the platinum versus non-
platinum doublets.22,23 The RR were higher with 
cisplatin but the OS outcomes remained the 
same. One review compared platinum therapy 
to non-platinum agents, with a 60% increase in 
the odds ratio for objective RR (P <0.0001) and a 
5% enhancement in patients’ 12-month survival 
(P <0.0003) in favour of cisplatin-based 
chemotherapy. It was also associated with reduced 
risk of death and less chemo-refractoriness, 
while a higher likelihood of response to platinum 
doublets was observed in the other trial.22,23 The 
rates of nausea, vomiting, delayed vomiting, 
myelosupression, nephrotoxicity, and gastro-
intestinal (GI) toxicity remained high with the 
platinum compounds. 
When cisplatin was compared with third 
generation agents, there was no difference in 
survival outcomes (P = 0.17), but it was associated 
with more neuropathy, more febrile neutropaenia, 
and toxic deaths. The third generation singlets 
were better tolerated, found less toxic in the case of 
ECOG performance status (PS) 2, and may also be 
an option in selected PS 3 patients, or in those who 
are elderly or with major co-morbidity. Moreover, 
third generation singlets remained a suitable option, 
when platinum compounds were contraindicated. 
Carboplatin was not found to be superior to these 
agents; in fact, it was associated with 11% higher 
mortality in non-squamous NSCLC. 
It is evident that the median survival of patients 
with advanced (IIIB) or metastatic (IV) NSCLC has 
enhanced substantially over the last few decades. 
For those receiving BSC, the median survival time 
is approximately 3–4 months, around 6 months for 
those receiving single agent platinum, and, when 
patients receive 4–6 cycles of cisplatin doublets 
(cisplatin plus a third generation agent), the median 
OS reaches 8–10 months.7 
The combination of cisplatin plus pemetrexed 
has lately emerged as standard of care in non-
squamous NSCLC, with a resultant median survival 
of 12.6 and 11.4 months for adenocarcinoma and 
large cell carcinoma subtypes, respectively, while 
The Cochrane Collaboration Group analysed 16 
randomised trials of more than 2,700 patients with 
advanced NSCLC.12 Platinum doublets were found 
to be associated with higher RR with an absolute 
benefit of 9% improvement in median OS at one 
year (i.e. 20%) using single agents versus 29% using 
doublets (P <0.0001). 
The Eastern Co-operative Oncology Group’s 
(ECOG) E1594 trial compared various third 
generation agents (paclitaxel, doxetaxel, or 
gemcitabine) in combination with a platinum 
compound.7 The response rates were 19% and 
the median survival was 9.2 months in females 
(n = 431) and 7 months in males (n = 726) and 
the one- and two-year survival rates were 30% 
and 10%, respectively. Other randomised clinical 
trials showed consistent results.13-17 Socinski et al. 
reported nab paclitaxel carboplatin use in advanced 
squamous histology where the combination was 
associated with a highly significant response rate 
of 41% versus 24% for cremophor paclitaxel and 
carboplatin, but there was no improvement in 
survival rates except in elderly.18
In 2006, the Doulliard meta-analyses 
comprising 7 randomised clinical trials, including 
2,867 patients, compared docetaxel to vinorelbine. 
The study confirmed a 11% reduction in the risk 
of death and a 43% reduction in the risk of febrile 
neutropaenia in favour of docetaxel.19 The impact 
of third generation drugs on the activity of first-line 
chemotherapy in advanced NSCLC was published 
in 2009 in a meta-analysis by Francesco Grossi. 
The study included 45 trials of 11,867 patients. The 
risk of immediate progression was found to be 14% 
lower with gemcitabine, a statistically insignificant 
9% lower with docetaxel, and 22% higher with 
paclitaxel. No risk of immediate progression was 
seen with vinorelbine.20 
Meta-analysis of poly-chemotherapy incor-
porating platinum triplets certainly improved 
response rates (P = 0.001), but neither showed 
improvement in progression-free survival (PFS) 
or OS (P = 0.88) and was certainly associated with 
higher toxicity.21 As a gold standard, platinum 
can be combined with any of the third generation 
agents (i.e. docetaxel, gemcitabine, vinorelbine, or 
irinotecan) with superior efficacy. The choice of 
agent generally depends on clinical parameters, 
drug availability, cost, patient convenience, and 
toxicity. Carboplatin is still widely used for patients 
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carboplatin plus gemcitabine or docetaxel has 
emerged as the best combination for treating the 
squamous subtype.24 Thus, histology for the first 
time emerged as a predictor for response, and the 
impression of one chemotherapy combination as 
the sole therapy for all histology has started to fade 
away.
To date, platinum doublets remain the mainstay 
of treatment in patients with ECOG PS 0–1 
[Table 1], and with marginally higher toxicity in PS 
2 patients.25 The absolute benefit of chemotherapy 
at one year varied according to the PS: in PS 0 and 1, 
the absolute benefit was 8%; in PS 2 the benefit was 
5%, and in PS 3 it was 4%.26
Lung cancer is a disease of the elderly and 
approximately one in every three patients is 70 
years or above. An equal number of patients have a 
PS of 3 or 4. Treatment of the elderly, and those with 
poor performance should be individualised.27 A 
third generation agent seems suitable, and there has 
been some evidence that these improved survival 
rates were as good as in younger patients when 
compared to BSC in the fit individuals with well-
preserved organ functions at the expense of higher 
toxicity.28 
In the last 5 years, the plateau in survival gains 
prompted researchers to drift either towards 
molecular profiling and targeting cells at the 
molecular level, or towards improving survival 
outcomes with maintenance therapy until patients 
experience best response or toxicity. BSC was 
considered superior to chemotherapy in the frail or 
elderly and for those with ECOG PS 3 or 4.7, 45
It had also been a matter of debate as to what 
constitutes the exact number of chemotherapy 
cycles in advanced NSCLC. By 2009, it had been 
established that “doublet chemotherapy should 
be administered for no more than 6 cycles” and 
for patients who attain either disease stabilisation 
or some response to induction chemotherapy, a 
treatment-free interval was offered.29 Initiation 
of a different chemotherapy prior to disease 
progression was not the norm. A focused update in 
2009 recommended that in patients with metastatic 
NSCLC, frontline platinum doublet should be 
discontinued at disease progression.29 Those who 
attain disease stabilisation should be offered a total 
of 4 chemotherapy cycles while those with any 
degree of benefit should be continued until 6 cycles 
have been achieved.29 
In recent times, the outcome of advanced and 
metastatic NSCLC has improved substantially with 
the integration of chemotherapy with biologics 
either sequentially or concurrent. The targeted 
agents include the EGFR-tyrosine kinase inhibitors 
(TKI) (erlotinib or gefitinib) and the corresponding 
chimeric EGFR-blocking antibody cetuximab, 
and the anti-angiogenic monoclonal antibody 
bevacizumab which targets the vascular endothelial 
growth factor (VEGF).30‒32 These agents are used 
as upfront therapy in combination with platinum 
doublets, and were based on large randomised 
clinical trials where they were continued beyond 
chemotherapy as maintenance therapy until 
progression of the disease or the appearance of 
toxicity.
Maintenance Therapy
The biologic basis of maintenance therapy is the 
Goldie-Coldman hypothesis which states that early 
use of non-cross resistant agents might increase 
the probability of killing more cells before resistant 
clones arise.33 Patients tolerating and responding to 
treatment with 4 cycles of chemotherapy may be 
treated with an additional two cycles. Maintenance 
therapy using single agent chemotherapy is offered 
until progression of the disease or appearance 
of toxicity, while ensuring that the PS does not 
deteriorate. On the contrary, the day model 
indicates that the most active drug regimens should 





0 Fully active, able to carry on all pre-disease 
performance without restriction
1 Restricted in physically strenuous activity but 
ambulatory and able to carry out work of a light 
or sedentary nature, e.g., light house work, office 
work
2 Ambulatory and capable of all self care but unable 
to carry out any work activities. Up and about 
more than 50% of waking hours
3 Capable of only limited self care, confined to bed 
or chair more than 50% of waking hours
4 Completely disabled. Cannot carry on any self 
care. Totally confined to bed or chair
5 Dead
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NSCLC progress after initial response to induction 
chemotherapy. Second-line chemotherapy impro-
ved PFS and enhanced the median OS. Soon et 
al. carried out a meta-analysis of 13 randomised 
trials between 1989 and 2008. Soon’s meta-
analysis was certainly influenced by a relatively 
large permetrexed maintenance therapy (JMEN) 
trial (excluding ATLAS and SATURN trials), 
comprised of over 3,000 patients, of which 10 of 
the 13 trials were done in the years after 2000.37–39 
The following facts were revealed in favour of 
maintenance therapy: 1) The improvement in OS 
was a statistically significant 8% reduction in the 
hazard of death (HR 0.92; 95%; confidence interval 
[CI] 0.86–0.99; P = 0.03) for continued therapy; 
2) It was not dependent on chemotherapy use, 
either platinum or third-generation agents; 3) The 
PFS improved with maintenance therapy, with a 
25% reduction in hazard for progression (HR 0.75; 
95% CI; 0.69–0.81; P <0.00001). The use of third-
generation agents was associated with higher 
PFS (P = 0.003) when compared to the older 
regimens; 4) Five of the 7 trials demonstrated major 
improvements in global quality of life (QoL) scores 
when using the maintenance chemotherapy arm; 
two of the 7 favoured the standard chemotherapy 
arm; 5) Two of the 7 trials suggested an increase 
in the adverse effects in the maintenance arm, 
especially myelotoxicity; 6) Cost of the drugs and 
associated hospital stays were reasons for concern.
There are numerous arguments against 
continuing chemotherapy in the palliative setting 
be used as a consolidation treatment to optimise 
results, and that treatment should be restricted to 
only 4–6 cycles.34 
The rationale for continued intervention is 
simple: if one waits, allowing a chemotherapy-
free interval, the disease progresses in roughly 
two months, with symptomatic deterioration and 
a possible fall in performance status. Offering 
immediate maintenance versus delayed salvage 
therapy at progression has always been an area of 
debate.35 
Switch maintenance therapy refers to the 
continuation of systemic therapy using a different 
non-cross-resistant drug from the patient’s initial 
chemotherapy regimen before disease progression. 
In a meta-analysis by Soon YY in 2009, patients 
with any degree of response or disease stabilisation 
were either subjected to maintenance treatment 
or were asked to watch and wait with intervention 
at progression.36 There was a 50% drop rate due 
to the deterioration of signs and symptoms or 
performance status in the watch and wait group, 
and only 50% were found fit enough to receive 
second-line therapy at progression. Therefore, the 
benefit of such an approach was questioned and 
instead Soon posited continuing chemotherapy 
until best response or toxicity. The hypothesis 
generated was meant to meet a primary endpoint 
of enhancement in PFS and an improvement in 
median OS with acceptable toxicity and tolerability 
while maintaining the PS. 
Virtually all patients with advanced, metastatic 
Table 2: Key phase III trials of switch maintenance therapy in non-small-cell lung carcinoma
Clinical Trials Treatment Arms No. 
Patients
PFS(m) OS (median)
Fidias et al.40 
2009
Gemcitabine Carboplatin- immediate Dx 







Capuzzo et al. 
(SATURN)39
Platinum doublet – Erlotinib (EGFR Mut) 









Ciuleanu et al. 
(JMEN)37
CG, PG, DG → Pemetrexed + BSC 









Takeda et al.43 
(WJTOG)
Platinum doublets x 6 




^22 vs 11 
*15.5 vs 7.7
Zhang et al.42 
(INFORM C-TONG 0804)
Platinum doublets + BSC 





^never smokers vs smokers; *Adenocarcinoma vs non-adenocarcinoma.
NS = not significant.
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as this is carried out without breaks in therapy, 
subjects advanced cancer patients to more toxicity, 
involves more trips to outpatient clinics, and 
increases the frequency of blood tests and/or 
transfusions. Maintenance may also be associated 
with poor QoL.35
The following text briefly describes trials and 
outcomes of effective, better-tolerated drugs that 
have emerged as agents to be used as maintenance 
therapy in selected lung cancer patients.
trials of switch maintenance 
Fidias et al. conducted a phase III trial of 309 
patients with advanced NSCLC who did not show 
progression after first-line treatment with 4 cycles 
of carboplatin-gemcitabine. The patients were 
randomised to receive immediate docetaxel versus 
delayed (at progression) treatment.40 Of those who 
enjoyed a chemotherapy holiday until progression of 
the disease, 37% had either deterioration of their PS 
or symptomatic deterioration, and therefore were 
not subsequent candidates for delayed docetaxel. 
However, of those in the maintenance arm, 95% 
could undergo immediate docetaxel. The two arms 
had similar RR, but the maintenance therapy was 
associated with significant improvement in PFS by 
three months (P = 0.0001). However, there was no 
difference in median OS (12.5 months, P = 0.08) in 
the delayed docetaxel arm. Though a negative trial, 
it is evident that a delay in salvage therapy resulted 
in a third of the patients falling short of subsequent 
intervention [Table 2].
Conducted by Cappuzzo et al., the SATURN 
study was a non-chemotherapy, large phase III 
randomised trial of 1,949 patients.39 Patients with 
adenocarcinoma subtypes were subjected to 
maintenance erlotinib  after 4 cycles of standard 
induction chemotherapy. The trial improved PFS 
by two months (P = 0.0001) and median OS by one 
month (12 versus 11 months, P = 0.0088) in favour of 
erlotinib. Subset analyses revealed a greater benefit 
for patients with EGFR mutations and, interestingly, 
patients having wild-type EGFR also derived benefit 
with maintenance erlotinib (11.3 versus 10.2 months, 
P = 0.0185). All histologic subtypes benefited, but 
adenocarcinoma and those with stable disease 
benefited the most (11.9 months for erlotinib versus 
9.6 months for placebo P = 0.0019). Based on the 
SATURN study39 and retrospective exploratory 
data from BR.21 trials, patients with squamous-cell 
carcinoma (SCC) also benefited from erlotinib after 
induction chemotherapy as second- or third-line 
salvage, but use of erlotinib as maintenance in SCC 
remains to be defined in the context of a clinical 
trial.41 A manageable acne-like rash and diarrhoea 
were the only toxicity reported with erlotinib use, 
but it was not cumulative and reduced over time.
The JMEN 663-patient trial involved 
pemetrexed treatment combined with BSC 
versus the use of a placebo plus BSC.37 The study 
revealed improvement in PFS by 2.5 months and 
a landmark 5.2 months improvement in OS in 
the adenocarcinoma subtypes (P = 0.0001). SCC 
histology had a detrimental effect on survival due 
to differential expression of thymidylate synthase, 
and the survival in SCC histology was indeed 
inferior by one month (P = 0.9). The trial included 
stage IIIB/IV NSCLC, PS 0–1 stable, or responding 
disease post-platinum doublets. Pemetrexed also 
has the advantage of ease of administration (a 10 
minute intravenous (IV) infusion) and therefore 
outpatient administration and superior tolerability 
with similar QoL scores. Pemetrexed maintenance 
was associated with higher but manageable toxicity 
(i.e. 16% in the pemetrexed arm versus 4% in the 
placebo arm) There was a 3% incidence of grade 3–4 
neutropenia versus 0% in the placebo group, and 5% 
of patients felt fatigue in the treatment arm versus 
1% in the placebo arm.
INFORM, a Chinese trial published by Zhang 
L. et al. used platinum doublets in non-progressing 
lung cancer patients who were subsequently 
randomised to receive gefitinib plus BSC versus 
BSC only.42 The PFS was superior in favor of the TKI 
arm but the OS remained the same.
In the West Japan Thoracic Oncology Group 
Trial, 600 chemotherapy-naïve, stage IIIB/IV 
patients with NSCLC (asymptomatic brain 
metatstases allowed, 31% non-smokers, 78% 
adenocarcinoma) were randomised to 6 cycles 
of platinum doublets versus 3 cycles followed by 
gefitinib maintenance.43 The gefitinib arm revealed 
improvement in PFS (P = 0.001) with a trend towards 
improvement in OS. Subset analyses showed 
doubling in median OS in non-smokers compared 
to smokers as well as in the adenocarcinoma 
subtypes in the gefitinib maintenance arm. 
A modest 1.2 months of improvement in 
median PFS was seen in a French IFC trial (EORTC 
08021) trial of maintenance gefitinib, but no gains 
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nor in the median survival (75 versus 60 weeks; P = 
0.243). 
Von Plessen et al. demonstrated, in another 
negative trial, that 6 versus 3 cycles of vinorelbine 
and carboplatin did not translate into a meaningful 
prolongation of PFS (21 versus 16 weeks; P = 0.21) or 
OS (32 versus 28 weeks; P = 0.75), and more blood 
transfusions were used in the maintenance arm.48
The use of gemcitabine as continuation therapy 
after initial treatment with 4 cycles of gemcitabine 
and cisplatin remains one of the most promising of 
the continuous maintenance therapies. Brodowicz 
et al. showed that maintenance therapy with 
gemcitabine resulted in a longer median time to 
progression (6.6 versus 5.0 months; P < 0.001) 
without any significant improvement in median OS 
(13 versus 11 months; P = 0.195).49 However a pre-
planned subgroup analysis revealed that in those 
with a Karnofsky performance status (KPS) score of 
greater than 80, the median survival doubled (25.3 
versus 12.2 months). Gemcitabine maintenance 
following gemcitabine carboplatin combination 
reported by Belani et al. was a negative trial for PFS 
(P 0.57) and OS (P 0.83), possibly because 66% of 
the patients had PS 2 and only 34% had a PS 0–1.50 
A subgroup analysis, where patients’ KPS was >80, 
clearly favoured the gemcitabine maintenance arm. 
Until those studies, continuation maintenance 
therapy was associated with a modest improvement 
in PFS with no gains in OS at the expense of 
more but manageable side-effects. KPS emerged 
as a strong predictor for response and a clinically 
meaningful outcome for maintenance therapy.
In the IFCT-GFPC 0502 French trial of 464 
were witnessed in the OS.44 Switch maintenance 
by virtue of increase in PFS and OS (pemetrexed 
or erlotinib) has emerged as a new standard of care 
in adenocarcinoma patients with preserved organ 
function who maintain PS 0–1, and therefore has 
been approved by the NCCN Guidelines version 
3.2012.45 
trials of continous maintenance 
Continuous maintenance refers to the prolonged 
use of one or more agents which the patient has 
been exposed to in his/her initial regimen in the 
absence of disease progression. There are several 
published randomised and ongoing clinical trials 
addressing the role of continuation maintenance 
therapy for advanced/metastatic NSCLC [Table 3]. 
Socinski et al. reported a negative trial of 230 
patients with advanced NSCLC.46 Patients were 
treated with carboplatin paclitaxel doublets for a 
total of 4 cycles and then were either subsequently 
treated with weekly paclitaxel until progression or 
given a chemotherapy-free interval (CFI). The same 
agent was then given again at disease progression. 
The continuation paclitaxel failed to improve 
the RR, the median survival rate, or QoL scores. 
However, the extended therapy arm resulted in a 
higher incidence of neuropathy; 40% compared to 
20% in the observation arm.
In 2003, Belani et al. described the use of weekly 
maintenance paclitaxel in 390 non-progressing 
advanced and metastatic NSCLC cases.47 Using 3 
different schedules of paclitaxel and carboplatin, 
the study revealed neither improvement in time to 
progression (TTP) (38 versus 29 weeks; P = 0.124) 
Table 3: Key phase II-III trials of continuous maintenance therapy in non-small-cell lung carcinoma
Clinical Trials Treatment Arms No. of Patients PFS Median 
OS (m)
Belani et al.47 Carboplatin Gemcitabine 
Carboplatin Gemcitabine → 
Gemcitabine
390 
-ive trial as 66% patients KPS<80
(P <0.124) (P <0.243)
Brodowicz et al.9 Cisplatin Gemcitabine 
Cisplatin Gemcitabine → Gemcitabine
519  








Perol et al.51 Cisplatin Gemcitabine → Gemcitabine 
Cisplatin Gemcitabine → Observation 
Cisplatin Gemcitabine → Erlotinib
464 3.8 (P <0.0001) 
1.9 
2.9 (P <0.002) 
P = NS
Paz-Ares et al.2 
(PARAMOUNT)
Cisplatin Pemetrexed → Pemetrexed + 









NS = not significant. 
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patients with stable disease or responders, 4 
cycles of cisplatin gemcitabine were used and later 
subgroups were continued on gemcitabine or a 
placebo, or were switched to erlotinib maintenance.51 
All patients who subsequently progressed were 
offered pemetrexed. PFS was superior in the 
erlotinib group (2.9 months; P = 0.002) versus the 
gemcitabine group (3.8 months; P <0.0001) versus 
the observation arm (1.9 months), but the OS was 
only numerically superior in the maintenance arms.
The PARAMOUNT trial incorporated 
maintenance pemetrexed in a phase III setting 
in patients receiving initial platinum pemetrexed 
doublets for 4 cycles. A group of 359 non-
progressive patients were randomly assigned to 
maintenance pemetrexed plus BSC, while 180 
patients were assigned to a placebo plus BSC. 
The test arm revealed superior PFS (4.1 months 
versus 2.8 months; P = 0.0006) in all age groups, 
irrespective of smoking status. All responders 
indicated an equal QoL, with 3–4% indicating grade 
3 or 4 toxicity including nausea, anaemia, fatigue, 
etc. However, fatigue was significant (5% versus 1% 
in those receiving ≤12 cycles) and may be managed 
by increasing the cycle interval to 4 weeks. The OS 
data were presented at the 2012 ASCO Conference 
where maintenance pemetrexed plus BSC was 
associated with a 22% reduction in risk of death 
(HR 0.78; 95% CI; 0.64-0.96) and the OS was 13.9 
versus 11 months for the placebo plus BSC group 
(P = 0.0195), and was maintained when calculated 
from the beginning of induction therapy (17 versus 
14 months). A third of the patients lived beyond 24 
months.52
FAST ACT-I was a phase II study by Tony Mok 
et al. employing platinum gemcitabine doublets 
every 4 weeks for 6 cycles in untreated stage IIIB/ 
IV NSCLC, concurrent with erlotinib or a placebo 
followed by continuous maintenance erlotinib in 
non-progressing patients in the experimental arm 
versus erlotinib at progression in the placebo arm.53 
PFS was increased, but not OS in the continuous 
maintenance arm. Based on this encouraging 
result, a phase III trial (FAST ACT-II) with a 
similar design has completed patient accrual in 
September 2010 and the results are keenly awaited.54 
Some institutes, including ours, finds it reasonable 
to continue pemetrexed, or gemcitabine, or 
erlotinib in patients with adenocarcinoma subtypes 
and gemcitabine in SCC. 
Based on the compelling data above, the focused 
update in 2011 recommended that a patient with 
any degree of clinical benefit after 4 cycles of 
frontline platinum doublet therapy, an immediate 
alternative, or a single agent should continue 
maintenance treatment. This should be offered 
for patients with adenocarcinoma subtype having 
PS 0–1.55 Maintenance therapy in frail and elderly 
patients should be individualised in the absence 
of controlled randomised trials. With their ease 
of administration at home, lack of the serious side 
effects that are generally seen with chemotherapy, 
and potential use in ECOG PS ≥2 patients, oral 
TKIs remain a viable therapeutic option in this set 
of patients.
molecular targets and 
monoclonal antibodies as 
maintenance 
Vascular Targets and Bevacizumab 
(Monoclonal antibody targeting the VEGF 
(vascular edothelial growth factor A)
Tumour angiogenesis has long been established. In 
1971, Folkman proposed a hypothesis regarding the 
presence of vascular factor, and it took almost two 
decades to discover vascular endothelial growth 
factor (VEGF).56 Tumours require a rich vascular 
supply in order to grow and metastasise. A tumour 
of 1–2 mm can survive without acquiring a blood 
supply, but as it grows it evolves an independent 
blood supply by the release of VEGF that binds 
to corresponding receptors (VEGFR), initiating 
angiogenesis, cell proliferation, invasion, and 
metastases. 
In a 2004 study whereby researchers locked 
VEGF pathways and thus tumourigenesis by 
monoclonal antibodies, patients showed higher 
response rates and superior survival outcomes. In 
the initial phase II trial of bevacizumab, two different 
dose schedules (7.5 and 15 mg/kg) were used, with 
a carboplatin paclitaxel doublet for a maximum of 6 
cycles, whereas in the third arm, bevacizumab was 
added to the same combination therapy at disease 
progression and maintained until best response 
or toxicity.57 Patients with SCC were excluded in 
subsequent trials because of an increased risk of 
fatal haemoptysis (9% pulmonary haemorrhage), 
especially if the lesions were cavitating, central, 
or adherent to a mediastinal blood vessel. Also 
excluded were patients with CNS metastases, due 
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ECOG E4599 trial [Table 4], the addition of 
bevacizumab to the paclitaxel and cisplatin arm 
was associated with enhanced RR (35% versus 
15%), superior PFS (6.2 versus 4.5 months), and a 
median OS (12.3 versus 10.3 months; P = 0.003).59 
 The one- and two-year survival rates improved 
from 44% to 56%, and 17% to 27%, respectively. 
Subgroup analyses revealed that patients with 
adenocarcinoma subtypes showed median 
survival improvement to 14.2 months (a 3.9 
month improvement). For those who developed 
to a fear of intra-tumoural bleed. RR were enhanced 
from 30% with platinum doublets to 40% with 
doublets plus bevacizumab at 15 mg/kg weight. 
The median PFS (7 months versus 5.9 months; P= 
0.023) and OS (17.7 months versus 14.9 months; P 
= 0.63) were superior in the 15 mg/kg bevacizumab 
arm. In another phase II Japanese trial, J 019907, 
paclitaxel and carboplatin were used alone or with 
bevacizumab, and the addition improved RRs and 
the PFS by one month (P = 0.009).58 
In an open label prospective, randomised, 
Table 4a: Key phase II-IV trials of addition of continuous Bevacizumab +M. Bev – therapy in non-small-cell lung 
carcinoma 
Author/ Study # of 
Patients




P value OS (m) P value

























Sandler et al. 
(ECOG E4599)59
      Subgroup analyses:
     -adenocarcinoma
     -developing hypertension














Reck Martin et al. 
(AVAIL)61
1043 III CDDP/ Gem 
+ Bev 7.5 mg/ kg 














Lucio Crino et al. 
(SAiL)62







740 III Platinum doublet + bev 
+ M. bev 













362 IIIb CDDP Pem Bev. 
+ M. Bev. 













Table 4b: Phase II & III trials of cetuximab in advanced metastatic non-small-cell lung carcinoma 
Study/Author # of 
Patients
Phase Regimen RR (%) PFS OS (m)
LUCAS76
Rosell






































RR = response rate; PFS = progression-free survival; OS = overall survival; Chemo = chemotherapy; +MBev = bevacizumab maintenance after 
induction with chemo + bevacizumab; Carb = carboplatin; Pac = paclitaxel; Pem = pemetrexed; Gem = gemcitabine; CCDP = cisplatin; Vin = 
vinorelbine; NS = not significant.
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hypertension (defined as >150/100 mm/Hg or a 20% 
increase in diastolic blood pressure (BP) from the 
baseline) because of bevacizumab, the median OS 
was longer (15.9 months; P = 0.03).59 In retrospect, 
subset analyses in patients above 70 years show a 
trend towards higher RR and PFS with the addition 
of bevacizumab, but there was no increase in OS 
(P = 0.4). It is not clear as yet if the improvement in 
efficacy was because of induction or because of the 
maintenance effects of bevacizumab. 
AVAIL was a randomised phase III trial using 
cisplatin, or gemcitabine and bevacizumab in three 
groups: Group A received chemotherapy alone; 
Group B received chemotherapy and 7.5 mg/kg 
of cisplatin, and Group C received chemotherapy 
plus 15 mg/kg of bevacizumab.61 The RRs improved 
(Group A - 22%; Group B - 38%; Group C - 35%) 
but there was no improvement in survival with the 
bevacizumab addition. The primary endpoint of the 
trial was not an investigation of maintenance.
SAIL, an open label phase IV trial of 2,212 
patients from 40 countries, analysed the addition 
of bevacizumab to platinum doublets followed 
by maintenance bevacizumab, which suggested 
an improvement in time to progression (TTP) to 
8+ months and a median OS to a landmark 19.3 
months.62 These figures were reproduced by another 
US-based study, ARIES, where the median OS also 
approached 13.6 months.63 
A phase II trial, combining pemetrexed-
carboplatin with or without bevacizumab also 
improved survival outcomes.64 The PFS was 8 
months and there was an OS of 14.6 months with 
the addition of bevacizumab. Based on these 
findings, a randomised trial (AVAPERL 1) was 
initiated in patients with advanced adenocarcinoma, 
incorporating pemetrexed-cisplatin with or without 
bevacizumab and then continued with maintenance 
bevacizumab, with or without pemetrexed.65 The 
maintenance combination of bevacizumab and 
pemetrexed revealed better RR and a superior 
PFS. The median OS was 15.6 months in the 
bevacizumab arm, which has not yet been reached 
in the bevacizumab-pemetrexed maintenance arm. 
In summary, the addition of bevacizumab to the 
standard platinum doublets gives a definitive hint at 
improving the median survival in adenocarcinoma 
subgroups way beyond the 12 months seen in PS 
0–1 patients. 
Information on continuing bevacizumab 
beyond progression came from preclinical data in 
animal xenografts, where it not only enhanced the 
effects of chemotherapy, but also delayed regrowth 
and improved survival.66 An observational study of 
bevacizumab use beyond progression in metastatic 
colorectal cancer has confirmed significant 
improvement in medial survival, from 26 months 
to 31 months.67 In a retrospective analysis from the 
electronic medical records of NSCLC in the US, in 
a total of 498 non-squamous NSCLC patients, 403 
received first line chemotherapy plus bevacizumab; 
154 received bevacizumab monotherapy on 
progression; and 249 did not. Median OS was 
20.9 months for the bevacizumab group versus 
10.2 months for the chemotherapy only group, 
and a PFS of 10.3 months for the bevacizumab 
group versus 6.5 months in the chemotherapy only 
group.68 A large multi-institutional, prospective, 
controlled randomised trial by Avastin in all lung 
lines was initiated by Roche Pharmaceuticals, and 
is currently recruiting patients.69 It incorporates 
induction platinum doublets plus bevacizumab 
which is continued post-progression, with salvage 
single-agent sequential chemotherapy with each 
progression in an attempt to improve survival 
figures, without compromising QoL and with 
acceptable toxicity. 
Miller et al. published the ATLAS, a phase 
III trial on advanced NSCLC patients (n = 768) 
treated with platinum doublets for 4 cycles using 
bevacizumab as a third agent during induction and 
then continued in non-progressing patients alone 
or with concurrent erlotinib.38 The combination 
arm had a superior PFS by 1.1 months (4.8 versus 3.7 
months; P = 0.0012), but there was no improvement 
in OS; therefore, it is a struggle to find a place for the 
use of two targeted agents in the presence of better 
options [Table 4]. The ongoing study design of the 
ERACLE trial (induction pEmetrexed and cisplatin 
followed by maintenance pemetrexed versus 
carboplatin-paclitaxel and bevacizumab followed 
by maintenance bevacizumab) compares the two 
drug combinations in non-squamous NSCLC in a 
maintenance setting.70 Point break trial is a negative 
trial for OS, yet the maintenance arm comprising 
of pemetrexed & bevacizumab revealed 1.7 & 2 
months improvement in PFS and OS respectively 
compared to bevacizumab maintenance alone.
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mutation did not predict the response to cetuximab. 
A retrospective analysis of FLEX trial reveals 
the maintenance cetuximab arm is associated 
with a significant improvement in median OS 
(1.3 months) in patients with stable disease while 
median survival was unchanged in patients with any 
kind of response.73 The US (BMS-099)74 trial looked 
at unselected patients with NSCLC to taxane plus 
cetuximab, and reached its primary endpoint of 
enhanced median OS (9.7 versus 8.4 months) but 
not PFS. A review by Pirker et al. (FLEX71, BMS 
09974, BMS 10075, LUCAS76 [see Table 4]) confirmed 
the consistent benefit of adding cetuximab to 
chemotherapy in patients with advanced NSCLC of 
all histological subtypes in terms of OS (P <0.01), 
PFS (P <0.03), and OS rate (OR 1.463, P <0.001).77
The Southwest Oncology Group trial is a phase 
II study that combined cetuximab to carboplatin, 
paclitaxel and bevacizumab for 6 cycles, followed 
by bevacizumab weekly until disease progression.78 
The primary endpoint of the trial was the frequency 
and severity of haemorrhagic toxicity that was 
grade 4 or higher in advanced stage non-squamous 
NSCLC and was found to have a tolerable safety 
profile with 2% incidence of haemorrhage that was 
grade > 4. SWOG 0819 is a similar, ongoing phase 
III trial comparing the same 4 drug combination 
with the 3 drug combination of ECOG 4599 trial.79 
Cetuximab was also evaluated concurrently with 
paclitaxel carboplatin or sequentially after the same 
regimen and then continued as maintenance. The 
outcomes were similar but sensory neuropathy was 
higher in the former (15% versus 5% P <0.036).80 
Acne-like rash, infusion related reactions and 
hypomagnesaemia were encountered in cetuximab 
recipients.
 Eight trials including 3,736 patients were 
analysed for either maintenance therapy for patients 
with any clinical benefit in NSCLC compared to 
watchful waiting or placebo. The study analyses 
included the OS as a primary outcome and PFS 
and toxicity as a secondary outcome. The switch 
maintenance was associated with improvement in 
OS (P <0.001), while the continuous arm showed 
a trend towards better OS but lacked statistical 
significance (P = 0.124). An interaction test was 
applied between the two maintenance therapies 
(switch and continuous), yet the difference in 
OS between the two maintenance strategies 
was not statistically significant (P = 0.777) and 
Epidermal Growth Factor Receptor and 
Cetuximab (Monoclonal Antibody Targeting 
the EGFR)
The First Line Erbitux in Lung Cancer (FLEX) trial 
was a phase III, prospective, randomised trial of 1,125 
patients from 155 treatment centres comparing the 
addition of cetuximab to cisplatin and vinorelbine 
given for 6 cycles.71 In the test arm, cetuximab was 
continued as maintenance until progression of 
disease or unacceptable toxicity. Median OS was 
11.3 months in the experimental arm (n = 557) 
and 10.1 months in the chemotherapy alone arm 
(n = 558 patients; P = 0.044). Interestingly, women 
survived longer than men (12.7 months versus 9.3 
in men), Asians did better compared to Caucasians 
(19.5 months versus 9.6), and patients with a better 
performance status, as well as those who had never 
smoked, did statistically better. Patients with an 
acne-like rash (grade 1–3 rash seen in 56%, grade 
3 in 10%) had a longer overall survival than those 
without (15 months versus 8.8; P <0.001). The 
addition of monoclonal antibodies improved the 
RRs, which was statistically significant (36% versus 
29%). Adenocarcinoma subtype (46% of overall 
patient population) expressing EGFR (defined as at 
least one EGFR protein on immunohistochemistry 
(IHC) showed a survival of 20.2 months in 
the experimental arm and 13.6 months in the 
chemotherapy-only arm.72 The researchers looked 
at the EGFR expression in a qualitative manner (i.e. 
product of the staining intensity [1+, 2+, 3+]) and 
the number of cells stained on IHC were scored 
between 0–300. A total of 30% of the patients had an 
EGFR H-score >200, which was considered strongly 
expressive, and a median survival of 12 months 
was seen in the cetuximab plus chemotherapy 
arm as compared to those with an EGFR H-score 
<200, which was considered negative, where the 
survival was 9.3 months (HR 0.75). Patients with 
SCC (34% of the patient population) had a median 
OS of 10.2 months in cetuximab group versus 8.9 
months in chemotherapy-only arm. A subgroup 
analysis revealed an EGFR overexpression in 30% 
of SCC patients, and when these were subjected 
to cetuximab and chemotherapy, the survival 
improved to 11.2 months for the combination arm 
versus 8.9 months for the chemotherapy-only arm, 
and also improved one-year survival to 44% in the 
combination arm versus 25% in the chemotherapy-
only arm. Unlike colon carcinoma, the k-ras 
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an improvement in PFS was found with both 
maintenance strategies (P = 0.128).81 Subgroup 
analyses could not find any differences in the 
survival outcome in switch maintenance using 
chemotherapy or that with the TKI. However, 
maintenance therapy was associated with higher 
toxicity. It is therefore reasonable to consider any 
maintenance therapy at the expense of reasonable 
toxicity and tolerability.
Conclusion
Maintenance therapy has emerged as a new 
treatment paradigm in the management of NSCLC. 
Patients with well-preserved organ function, 
who are maintaining their PS and responding to 
chemotherapy, or who are experiencing disease 
stabilisation after induction chemotherapy may 
now be effectively treated with maintenance 
therapy, taking tolerability into account. Others 
may be followed closely and therapy may be 
individualised according to clinical course, 
age, and the presence of co-morbidity. Salvage 
chemotherapy may be instituted at any time before 
the PS declines to levels beyond intervention, or 
the patient experiences significant symptomatic 
deterioration. Careful patient and drug selection, 
long term safety, and QoL should all be considered 
while patient participation remains integral in 
final decision making. Details of patients’ clinical 
features, histology, and genetics should be taken 
into account for optimisation of therapy [Tables 5a 
and b]. However, retrospective data and subgroup 
analyses should be read with extreme caution, as 
the number of patients in these analyses are often 
Table 5a: Maintenance strategies in non-small-cell lung carcinoma
Maintenance Strategies (Options): 
Adenocarcinoma Subtypes:
1. Switch maintenance
    Induction Chemotherapy
    Gemcitabine + Carboplatin/ or Cisplatin 
    Pemetrexed + Cisplatin 
    Pemetrexed + Cisplatin 
    Gemcitabine/or docetaxel/ or Paclitaxel + Cisplatin
Maintenance Agent
Docetaxel 




    Pemetrexed + Cisplatin 
    Gemcitabine + Cisplatin




3. Monoclonal Antibody Addition:
    Platinum doublets + ‡Bevacizumab 




    Platinum + Gemcitabine/ or docetaxel + §Cetuximab §Cetuximab
†Gemcitabine
*May be used in frail & elderly; †KPS>80; ‡In nonsquamous histology only tumor not abutting major vessel and no hemoptysis; §data favors use in 
cases with stable disease after post induction chemotherapy.
Table 5b: Maintenance therapy in non-small-cell lung 
carcinoma
Who gets maintenance therapy?
(Non-small-cell lung carcinoma):
Histology:
   Adenocarcinoma subtypes
   Squamous cell carcinoma
Clinical Features:
Age: Adults 18-70 years (fit, elderly)
Gender: Any
ECOG PS 0-1, †KPS>80 
ECOG PS 2 (selected cases for TKI)
Genetics:
EGFR Wild type - chemotherapy
EGFR Mutant - *TKI
(TKI responders; Asian, women, never smoker, having 
adenocarcinoma)
k-ras mutation - chemotherapy
EML4 Alk - Crizotinib
Suitable subset of patients;




*May also be used in frail & elderly; ‡In nonsquamous histology only 
tumor not abutting major vessel and no hemoptysis; §data favors use in 
cases with stable disease after post induction chemotherapy.
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reduced and the studies are subject to biases.
Patient and tumour characteristics derived from 
molecular biology and cancer genetics continue to 
evolve and are helping oncology decision-makers to 
define subsets of patients that would derive benefit 
from customised maintenance therapy. The data 
from large numbers of randomised phase III trials 
is very compelling, and the year 2012 provided a 
variety of options for treating any given patient, but 
what remains to be defined is the exact sequencing 
of these strategies. 
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